The helper's high is not a metaphor In 1988, sociologist Allan Luks surveyed over 3,000 volunteers across the United States ...

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been ...

But some commonly prescribed drugs interfere with these processes, making it harder to stay cool. Here are a few you should ...

Otsuka’s daily attention-deficit/hyperactivity disorder (ADHD) candidate has shown benefit in a Phase IIIb trial. In the study (NCT06973577), centanafadine XR 280mg once daily was investigated in ...

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective ...

Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug ...

First-line serotonergic antidepressants achieve clinical response in approximately 60–65% of patients with persistent postural-perceptual dizziness (PPPD), leaving a substantial refractory population.

We are all constantly in search of dopamine. A lot rests on our brains producing enough of it. And our diet plays a big part in that equation. We spoke to experts about the importance of dopamine in ...

Lately, it seems like everyone is nostalgic for the '90s — and I have to say, I wholeheartedly agree. As a child of the decade, there was something so magical about a time where screens were limited ...